VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
VBI Vaccines, Inc. - Ordinary Shares (VBIV)
Last vbi vaccines, inc. - ordinary shares earnings: 11/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
vbivaccines.com/investors
Company Research
Source: GlobeNewswire
Vaccination complete in 1,537 subjects in PROTECT Phase 3 studyNo vaccine-related adverse events have been observed to-dateTop-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the last subject has received the last vaccination in the PROTECT Phase 3 study of Sci-B-Vac®, the company’s third-generation prophylactic hepatitis B vaccine. Additionally, the independent Data and Safety Monitoring Board has reviewed all safety data from the global Phase 3 program available to-date and has not identified any safety signals or vaccine-related adverse events. Top-line data from this study are expected mid-2019. The PROTECT study is one of two ongoing global pivotal studies that form the Phase 3 program for Sci-B-Vac®. With 27 sites across the U.S., Europe, and Canada, PROTECT is desi
Show less
Read more
Impact Snapshot
Event Time:
VBIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VBIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VBIV alerts
High impacting VBI Vaccines, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
VBIV
News
- VBI Vaccines Inc. (NASDAQ: VBIV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- VBI Vaccines Reports Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- VBI Vaccines Reports Full Year 2023 Financial ResultsBusiness Wire
- VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesBusiness Wire
VBIV
Earnings
- 11/14/23 - Miss
VBIV
Sec Filings
- 4/17/24 - Form SC
- 4/16/24 - Form 10-K
- 4/16/24 - Form 8-K
- VBIV's page on the SEC website